Skip to main content

Table 1 Characteristics of the included studies

From: The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis

First author (year)

Country

Time span

Case number (low/high)

Histological type

TNM

Antibody source

Counting method

Cutoff (positive)

Subcellular localization

Outcome

NOS score

Takanami (2003)

Japan

1992–1996

71(29/42)

NSCLC

I-III

R&D

P

10%

membrane and/or cytoplasm

NA

6

Spano (2004)

France

1987–1999

61(44/17)

NSCLC

I

Abcam

S + P

scores = 6/9

nucleus

OSa

8

Su (2005)

China

NA

34 (17/17)

NSCLC

I-III

R&D

S

 ≥ normal

membrane and/or cytoplasm

NA

6

Na (2008)

Germany

NA

46 (24/22)

NSCLC

I-IV

Abcam

S

scores = 3

cytoplasm/nucleus

NA

6

Song (2008)

Korea

1995–1999

323 (275/48)

NSCLC

I-IV

Abcam

P

 > 50%

cytoplasm and nucleus

OS/DFSa

7

Suzuki (2008)

Japan

1995–2000

90(68/22)

NSCLC

I-IV

Santa Cruz

P

 ≥ 10%

membrane and/or cytoplasm

OSa

6

Wagner (2009)

America

NA

154(92/62)

NSCLC

I-IV

R&D

S

scores ≥ 2

membrane/nucleus

DFS

7

Chen (2011)

China

1998.1–2008.6

64(13/51)

NSCLC

I-IV

Abcam

S + P

scores ≥ 3

membrane and/or cytoplasm

NA

8

Otsuka (2011)

Canada

2003–2006

170(141/29)

NSCLC

IV

Abcam

AQUA

scores ≥ 3371

cytomembrane

OSa

8

Wang (2011)

China

2002–2004

208(91/117)

NSCLC

I-III

R&D

S + P

scores ≥ 2

cytoplasm

OS

8

Zhou (2012)

China

2002.6–2006.12

105(33/62)

NSCLC

III

Boao Sen

S + P

scores ≥ 4

cytoplasm

NA

6

Al Zobair (2013)

China

NA

125(63/62)

NSCLC

I-IV

Abcam

S + P

scores ≥ 2

cytoplasm

OS

8

Li (2014)

China

1999–2009

50(15/35)

SCLC

I-IV

R&D

S + P

scores > 2

membrane and/or cytoplasm

OSa

9

Wang (2014)

China

1998.1–2008.1

105(42/63)

NSCLC

I-IV

Abcam

S + P

scores ≥ 4

NA

NA

7

Kaemmerer (2015)

Germany

1998–2011

90(23/47)

BP-NEN

NA

UMB-2

S + P

scores ≥ 5

membrane

OSa

8

Li (2015)

China

2003.6–2009.10

65(31/34)

SCLC

I-III

Abcam

S + P

scores ≥ 6

cytoplasm

OSa

6

  1. NSCLC Non-small cell lung cancer, BP-NENS Bronchopulmonary neuroendocrine neoplasms, AC Adenocarcinoma, ASC Adenosquamous carcinoma, S Staining intensity, P Percentage of positively-stained cells, HR Hazard ratio
  2. aextracted from the Kaplan–Meier survival curves, OS Overall survival, DFS Disease-free survival, DSS Disease specific survival, NOS Newcastle–Ottawa Scale, NA Not available